NCT03251248View on ClinicalTrials.gov

Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

August 22, 2017

Primary Completion Date

May 8, 2018

Study Completion Date

October 17, 2018

Conditions
Healthy
Interventions
DRUG

MSB11455

Subjects will receive MSB11455 either on Period 1 Day 1 or Period 2 Day 1.

DRUG

Neulasta

Subjects will receive Neulasta either on Period 1 Day 1 or Period 2 Day 1.

Trial Locations (2)

3004

Nucleus Network, Melbourne

4006

Q-Pharm Pty Ltd, Herston

All Listed Sponsors
lead

Fresenius Kabi SwissBioSim GmbH

INDUSTRY

NCT03251248 - Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects | Biotech Hunter | Biotech Hunter